Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01314898 · ClinicalTrials.gov registry record · Phase 1
A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy Volunteers
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01314898 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 12 participants.
The verdict
NCT01314898, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
24-hr urinary sodium/potassium ratio will be a sensitive biomarker of antimineralocorticoid activity. The dose-response relationship of the antimineralocorticoid activity of PF-03882845 can be established following single oral doses.
Interventions
- DRUG Spironolactone
- DRUG 3 mg PF-03882845
- DRUG 10 mg PF-03882845
- DRUG 30 mg PF-03882845
- DRUG 100 mg PF-03882845
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-03 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01314898
The ClinicalTrials.gov registry entry for NCT01314898 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Spironolactone is the first listed.
NCT01314898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01314898 about?
NCT01314898 is a clinical study titled "A Single Dose Study Of Antimineralocorticoid Activity Of PF-03882845 In Healthy Volunteers". 24-hr urinary sodium/potassium ratio will be a sensitive biomarker of antimineralocorticoid activity. The dose-response relationship of the antimineralocorticoid activity of PF-03882845 can be established following single oral doses.
What is the current status of trial NCT01314898?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2011-03. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01314898?
The interventions under investigation include: Spironolactone (DRUG), 3 mg PF-03882845 (DRUG), 10 mg PF-03882845 (DRUG), 30 mg PF-03882845 (DRUG), 100 mg PF-03882845 (DRUG).
Who is sponsoring clinical trial NCT01314898?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.